BR112021010134A2 - Métodos de tratamento de transtornos mieloproliferativos - Google Patents
Métodos de tratamento de transtornos mieloproliferativos Download PDFInfo
- Publication number
- BR112021010134A2 BR112021010134A2 BR112021010134-9A BR112021010134A BR112021010134A2 BR 112021010134 A2 BR112021010134 A2 BR 112021010134A2 BR 112021010134 A BR112021010134 A BR 112021010134A BR 112021010134 A2 BR112021010134 A2 BR 112021010134A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- individual
- ruxolitinib
- treatment
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/062534 WO2020112086A1 (en) | 2018-11-27 | 2018-11-27 | Methods of treating myeloproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021010134A2 true BR112021010134A2 (pt) | 2021-08-24 |
Family
ID=64734125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021010134-9A BR112021010134A2 (pt) | 2018-11-27 | 2018-11-27 | Métodos de tratamento de transtornos mieloproliferativos |
Country Status (8)
| Country | Link |
|---|---|
| JP (2) | JP7453230B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250004357A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018451360B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021010134A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120973A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202191489A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202105279SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020112086A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020112939A1 (en) | 2018-11-27 | 2020-06-04 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| WO2020112086A1 (en) * | 2018-11-27 | 2020-06-04 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021320151A1 (en) * | 2020-08-04 | 2023-02-23 | Constellation Pharmaceuticals, Inc. | 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide for treating thrombocythemia |
| CN122439254A (zh) | 2024-01-18 | 2026-07-21 | 株式会社Lg新能源 | 电极组件、二次电池和电池单元 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| CN106687463B (zh) | 2014-06-20 | 2019-04-09 | 星座制药公司 | 一种乙酰胺类化合物的晶型 |
| WO2020112086A1 (en) * | 2018-11-27 | 2020-06-04 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
-
2018
- 2018-11-27 WO PCT/US2018/062534 patent/WO2020112086A1/en not_active Ceased
- 2018-11-27 KR KR1020247040010A patent/KR20250004357A/ko active Pending
- 2018-11-27 AU AU2018451360A patent/AU2018451360B2/en active Active
- 2018-11-27 KR KR1020217019508A patent/KR102738936B1/ko active Active
- 2018-11-27 JP JP2021530108A patent/JP7453230B2/ja active Active
- 2018-11-27 CA CA3120973A patent/CA3120973A1/en active Pending
- 2018-11-27 BR BR112021010134-9A patent/BR112021010134A2/pt not_active Application Discontinuation
- 2018-11-27 SG SG11202105279SA patent/SG11202105279SA/en unknown
- 2018-11-27 EA EA202191489A patent/EA202191489A1/ru unknown
-
2024
- 2024-03-07 JP JP2024034717A patent/JP2024063214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020112086A1 (en) | 2020-06-04 |
| JP7453230B2 (ja) | 2024-03-19 |
| CA3120973A1 (en) | 2020-06-04 |
| KR102738936B1 (ko) | 2024-12-06 |
| SG11202105279SA (en) | 2021-06-29 |
| EA202191489A1 (ru) | 2021-09-10 |
| AU2018451360B2 (en) | 2022-05-26 |
| KR20210095904A (ko) | 2021-08-03 |
| KR20250004357A (ko) | 2025-01-07 |
| JP2024063214A (ja) | 2024-05-10 |
| JP2022519425A (ja) | 2022-03-24 |
| AU2018451360A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102738936B1 (ko) | 골수증식 장애의 치료 방법 | |
| US12070464B2 (en) | Methods of treating myeloproliferative disorders | |
| O'Sullivan et al. | JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms | |
| MX2012014416A (es) | Tratamiento de cancer de sangre. | |
| Bournia et al. | Recent advances in the treatment of systemic sclerosis | |
| TW202128212A (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 | |
| US20240269146A1 (en) | Use of pelabresib for treating anemias | |
| KR20230110751A (ko) | 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제 | |
| EA047870B1 (ru) | Способы лечения миелопролиферативных расстройств | |
| WO2021091532A1 (en) | Methods of treating myeloproliferative disorders | |
| WO2020256739A1 (en) | Methods of treating myeloproliferative disorders | |
| AU2020422620B2 (en) | Use of ketamine in the treatment of cachexia | |
| WO2025002346A1 (zh) | 含pd-l1小分子抑制剂的药物组合及其应用 | |
| CN112294817B (zh) | 多韦替尼用于治疗高尿酸相关疾病的用途 | |
| WO2021014812A1 (ja) | 線維芽細胞性又は筋線維芽細胞性腫瘍・疾患の治療 | |
| KR20230048042A (ko) | 혈소판 증가증의 치료를 위한 2-((4s)-6-(4-클로로페닐)-1-메틸-4h-벤조[c]이속사졸로[4,5-e]아제핀-4-일)아세트아미드 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |